Literature DB >> 26074712

3.0T ¹H magnetic resonance spectroscopy for assessment of steatosis in patients with chronic hepatitis C.

Qian Zhang1, Hui-Mao Zhang1, Wen-Qian Qi1, Yong-Gui Zhang1, Ping Zhao1, Jian Jiao1, Jiang-Bin Wang1, Chun-Yu Zhang1.   

Abstract

AIM: To investigate the utility of (1)H magnetic resonance spectroscopy ((1)H MRS) as a noninvasive test for steatosis in patients infected with hepatitis C virus.
METHODS: Ninety patients with chronic hepatitis C and pathology data underwent 3.0T (1)H MRS, and the results of MRS and pathological analysis were compared.
RESULTS: This group of patients included 26 people with mild fatty liver (28.89%), 16 people with moderate fatty liver (17.78%), 18 people with severe fatty liver (20.0%), and 30 people without fatty liver (33.33%). The water peak was near 4.7 parts per million (ppm), and the lipid peak was near 1.3 ppm. Analysis of variance revealed that differences in the lipid peak, the area under the lipid peak, ratio of the lipid peak to the water peak, and ratio of the area under the lipid peak to the area under the water peak were statistically significant among the groups. Specifically, as the severity of fatty liver increased, the value of each index increased correspondingly. In the pairwise comparisons, the mean lipid peak, area under the lipid peak, ratio of the lipid peak to the water peak, and ratio of the area under the lipid peak to the area under the water peak were significantly different between the no fatty liver and moderate fatty liver groups, whereas no differences were noted between the severe fatty liver group and the mild or moderate fatty liver group. Area under the ROC curve (AUC) of area ratio in lipid and water and ratio in lipid and water in the no fatty liver group to mild fatty liver group, mild fatty liver group to moderate fatty liver group, and moderate fatty liver disease group to severe fatty liver group, were 0.705, 0.900, and 0.975, respectively.
CONCLUSION: (1)H MRS is a noninvasive technique that can be used to provide information on the effect of liver steatosis on hepatic metabolic processes. This study indicates that the (1)H MRS can be used as an indicator of steatosis in patients with chronic hepatitis C.

Entities:  

Keywords:  1H; Antiviral therapy; Hepatitis C; Magnetic resonance spectroscopy

Mesh:

Substances:

Year:  2015        PMID: 26074712      PMCID: PMC4458784          DOI: 10.3748/wjg.v21.i21.6736

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

1.  European guideline for the management of hepatitis B and C virus infections, 2010.

Authors:  G Brook; V Soriano; C Bergin
Journal:  Int J STD AIDS       Date:  2010-10       Impact factor: 1.359

Review 2.  Global challenges in liver disease.

Authors:  Roger Williams
Journal:  Hepatology       Date:  2006-09       Impact factor: 17.425

Review 3.  Assessment of in vivo 1H magnetic resonance spectroscopy in the liver: a review.

Authors:  Frank Fischbach; Harald Bruhn
Journal:  Liver Int       Date:  2008-03       Impact factor: 5.828

4.  [No-invasive determination of liver fat with 1H-MR spectroscopy].

Authors:  Jochem R van Werven; Aart J Nederveen; Jaap Stoker
Journal:  Ned Tijdschr Geneeskd       Date:  2011

5.  Hepatic MR imaging for in vivo differentiation of steatosis, iron deposition and combined storage disorder: single-ratio in/opposed phase analysis vs. dual-ratio Dixon discrimination.

Authors:  Mustafa R Bashir; Elmar M Merkle; Alastair D Smith; Daniel T Boll
Journal:  Eur J Radiol       Date:  2011-02-16       Impact factor: 3.528

6.  A comparison of MR elastography and 31P MR spectroscopy with histological staging of liver fibrosis.

Authors:  Edmund M Godfrey; Andrew J Patterson; Andrew N Priest; Susan E Davies; Ilse Joubert; Anant S Krishnan; Nyree Griffin; Ashley S Shaw; Graeme J Alexander; Michael E Allison; William J H Griffiths; Alexander E S Gimson; David J Lomas
Journal:  Eur Radiol       Date:  2012-07-01       Impact factor: 5.315

7.  1H-MRS of hepatic fat using short TR at 3T: SNR optimization and fast T2 relaxometry.

Authors:  Giulio Gambarota; Mark Tanner; Marinette van der Graaf; Robert V Mulkern; Rexford D Newbould
Journal:  MAGMA       Date:  2011-09-04       Impact factor: 2.310

8.  Non-invasive means of measuring hepatic fat content.

Authors:  Sanjeev-R Mehta; E-Louise Thomas; Jimmy-D Bell; Desmond-G Johnston; Simon-D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

9.  The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis.

Authors:  Anneloes E Bohte; Jochem R van Werven; Shandra Bipat; Jaap Stoker
Journal:  Eur Radiol       Date:  2010-07-31       Impact factor: 5.315

10.  An investigation of human brain tumour lipids by high-resolution magic angle spinning 1H MRS and histological analysis.

Authors:  Kirstie S Opstad; B Anthony Bell; John R Griffiths; Franklyn A Howe
Journal:  NMR Biomed       Date:  2008-08       Impact factor: 4.044

View more
  4 in total

Review 1.  [Functional MR imaging of the liver].

Authors:  A Wibmer; R Nolz; M Trauner; A Ba-Ssalamah
Journal:  Radiologe       Date:  2015-12       Impact factor: 0.635

Review 2.  Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease.

Authors:  Shujing Lv; Sushan Jiang; Shousheng Liu; Quanjiang Dong; Yongning Xin; Shiying Xuan
Journal:  J Clin Transl Hepatol       Date:  2018-06-22

3.  TRIB1 rs17321515 and rs2954029 gene polymorphisms increase the risk of non-alcoholic fatty liver disease in Chinese Han population.

Authors:  Qun Liu; Feng Xue; Jing Meng; Shou-Sheng Liu; Li-Zhen Chen; Hui Gao; Ning Geng; Wen-Wen Jin; Yong-Ning Xin; Shi-Ying Xuan
Journal:  Lipids Health Dis       Date:  2019-03-09       Impact factor: 3.876

4.  Systematic Review and Meta-analysis of Circulating Fetuin-A Levels in Nonalcoholic Fatty Liver Disease.

Authors:  Shousheng Liu; Jianhan Xiao; Zhenzhen Zhao; Mengke Wang; Yifen Wang; Yongning Xin
Journal:  J Clin Transl Hepatol       Date:  2020-12-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.